Stem Cell Injections: Types, Procedure, Costs, and How to Find a Qualified Provider

What Are Stem Cell Injections?

Stem cell injections refer to procedures in which concentrated biological preparations containing stem cells or progenitor cells are injected into damaged tissues to promote healing and reduce inflammation. The term is used broadly in clinical practice and marketing, though not all products labeled as “stem cell injections” contain the same types or concentrations of cells [1].

The goal is to harness the body’s own repair mechanisms (or those of donor cells) to restore function in damaged tissue rather than simply managing symptoms or replacing a joint surgically. The science is promising and rapidly evolving, but marketing has often outpaced the evidence. Understanding exactly what is being injected and what the data shows is the best defense against unrealistic expectations.

Types of Stem Cell Injections

Platelet-Rich Plasma (PRP)

PRP is not technically a stem cell product, but it is frequently grouped with stem cell injections because it falls under the same regenerative medicine umbrella and is often used alongside cell-based therapies.

PRP is produced by drawing the patient’s blood (typically 30 to 60 mL), spinning it in a centrifuge to concentrate platelets, and injecting the preparation into the target tissue. Platelets contain growth factors such as PDGF, TGF-beta, and VEGF, which support tissue repair and modulate inflammation [2].

PRP has the most clinical evidence of any regenerative injection, with systematic reviews showing benefit for knee osteoarthritis and tendon conditions like lateral epicondylitis and patellar tendinopathy [3]. It is the least expensive option and carries minimal risk. The main limitation is that PRP does not contain stem cells in meaningful numbers.

Bone Marrow Aspirate Concentrate (BMAC)

BMAC is obtained by aspirating bone marrow (usually from the iliac crest) and concentrating it with a centrifuge. The concentrate contains MSCs, hematopoietic stem cells, platelets, growth factors, and anti-inflammatory cytokines [4]. The entire process can be completed in a single procedure without laboratory expansion, making it a true “point-of-care” therapy.

MSC concentration in BMAC varies by patient age, health status, and aspiration technique, typically ranging from 500 to 50,000 MSCs per milliliter [4]. The FDA generally considers autologous, same-day BMAC to be minimally manipulated and intended for homologous use, exempting it from premarket approval requirements [5].

Adipose-Derived Stromal Vascular Fraction (SVF)

SVF is obtained from a small-volume lipoaspiration procedure (essentially a mini-liposuction), followed by enzymatic digestion or mechanical processing to separate the cellular components from the fat. The resulting SVF contains adipose-derived MSCs, endothelial progenitor cells, pericytes, macrophages, and other stromal cells [6].

Adipose tissue contains MSCs at 100 to 500 times the concentration found in bone marrow. However, the FDA considers enzymatic digestion of adipose tissue to be more than minimal manipulation, meaning SVF prepared with collagenase is regulated as a biologic requiring premarket approval. Mechanically processed fat (such as microfragmented adipose tissue) may fall under a different classification, though this remains debated [5].

Umbilical Cord-Derived MSCs

Allogeneic MSCs derived from umbilical cord tissue (Wharton’s jelly) or amniotic tissue represent the newest category of stem cell injectables in clinical use. These are donor-derived products, meaning the cells come from a source other than the patient.

UC-MSCs offer theoretical advantages: the cells are young, highly proliferative, and can be prepared as an “off-the-shelf” product [7]. However, this category carries the most caveats. Many commercial “umbilical cord stem cell” products contain few or no viable stem cells by the time they reach the patient. Independent analyses have found that some products contain no living MSCs at all, despite being marketed as stem cell therapies [8].

Patients considering allogeneic products should ask about cell viability data, tissue bank certifications, and whether independent testing has confirmed living stem cells in the final product.

Orthopedic Applications

Knee Osteoarthritis

Knee osteoarthritis is by far the most common indication for stem cell injections. Patients with mild to moderate cartilage degeneration (Kellgren-Lawrence grades 1 through 3) are generally considered the best candidates, as these patients still have enough cartilage remaining to benefit from regenerative support. Patients with severe, bone-on-bone arthritis (grade 4) are less likely to achieve meaningful cartilage regeneration and may be better served by joint replacement [9].

Clinical studies of intra-articular stem cell injections for knee OA have generally shown improvements in pain (as measured by visual analog scales and WOMAC scores) and functional outcomes over 6 to 24 months. Some MRI-based studies have demonstrated stabilization or modest improvement in cartilage thickness, though the clinical significance of these imaging findings is still being evaluated [10].

Hip Degeneration

Hip osteoarthritis and labral tears are increasingly treated with regenerative injections, though the evidence base is smaller than for knee applications. Intra-articular injections for the hip typically require fluoroscopic (X-ray) guidance because the hip joint is deeper and more difficult to access than the knee. Early clinical data is encouraging, with some studies reporting pain reduction and functional improvement, though randomized controlled trials are limited [11].

Shoulder Injuries

Rotator cuff tears, particularly partial-thickness tears, are a growing application for stem cell and PRP injections. The rationale is that partial tears in tendons with poor blood supply may benefit from the growth factors and cellular support provided by regenerative injections. A systematic review of PRP and stem cell injections for rotator cuff pathology found evidence of reduced pain and improved function, with some studies showing improved tendon healing rates on follow-up imaging [12].

Tendon and Ligament Injuries

Achilles tendinopathy, plantar fasciitis, tennis elbow, and other tendon conditions have been treated with PRP and stem cell injections with varying degrees of success. PRP has the strongest evidence in this category, with multiple randomized trials supporting its use for chronic tendinopathy that has not responded to conservative treatment [3].

What the Procedure Looks Like

Pre-Procedure

Before a stem cell injection, patients typically undergo a clinical evaluation and imaging (X-ray and/or MRI) to assess the extent of tissue damage and confirm candidacy. Many providers recommend stopping non-steroidal anti-inflammatory drugs (NSAIDs) 1 to 2 weeks before the procedure, as these medications may inhibit platelet function and interfere with the healing response. Blood thinners may also need to be adjusted in consultation with the prescribing physician.

Harvesting (If Autologous)

For BMAC, bone marrow aspiration is performed from the posterior iliac crest under local anesthesia. A specialized needle is inserted into the marrow space, and the aspiration takes 15 to 30 minutes. The aspirate is processed in a bedside centrifuge to concentrate cells and platelets.

For SVF, a small lipoaspiration is performed under local anesthesia from the abdomen or flanks. For allogeneic products, no harvesting is needed; the product arrives frozen or fresh from a tissue bank.

The Injection

The cell preparation is injected into the target tissue using image guidance. Ultrasound ensures accurate placement for joints and tendons, while fluoroscopy (live X-ray) is used for deeper joints like the hip. The injection is similar to a cortisone injection in technique, with the entire procedure taking 30 to 60 minutes.

Recovery Timeline

Recovery from a stem cell injection is generally straightforward compared to surgical alternatives:

• Days 1 to 3: Mild to moderate soreness and swelling at the injection site. Ice, elevation, and acetaminophen (not NSAIDs) are typically recommended.
• Week 1 to 2: Gradual reduction in post-procedure soreness. Most patients can return to desk work and light daily activities within a few days.
• Weeks 2 to 6: Progressive return to normal activities. Low-impact exercise (walking, swimming, stationary cycling) is usually encouraged. High-impact activities and heavy lifting are typically restricted.
• Months 2 to 6: Gradual improvement in symptoms as the biological response develops. The full benefit of stem cell injections may not be apparent for 3 to 6 months, as tissue remodeling and repair are slow processes.

Cost and Insurance

Stem cell injections are rarely covered by health insurance in the United States, as most commercial payers and Medicare consider them experimental or investigational. Out-of-pocket costs vary widely depending on the type of product, geographic location, and clinic pricing structure.

• PRP injection: $500 to $2,000 per treatment
• BMAC (bone marrow concentrate): $3,000 to $7,000 per treatment area
• SVF (adipose-derived): $4,000 to $8,000 per treatment area
• Allogeneic MSC products: $3,000 to $10,000+ per treatment area

Some clinics offer package pricing for multiple joints or combination protocols. Be wary of clinics offering large discounts for upfront payment or high-interest financing. Weigh the cost against the alternatives: physical therapy, cortisone injections, viscosupplementation, and surgical intervention.

How to Vet a Provider

The stem cell injection market includes both highly qualified, evidence-based practitioners and unscrupulous operators making exaggerated claims. Knowing how to evaluate a provider is one of the most consequential decisions a patient can make.

Questions to Ask

• What exactly is being injected? A qualified provider should be able to tell you precisely what product they use, where it comes from, and what it contains. Vague answers (“stem cells” without specifics) are a red flag.
• What is the evidence for this treatment in my condition? Good providers will be honest about the current state of the evidence, including its limitations.
• How many of these procedures have you performed? Experience matters. Ask about their training in regenerative medicine specifically.
• Do you use image guidance? Injections without ultrasound or fluoroscopy guidance have lower accuracy and should generally be avoided for joint and tendon applications.
• What outcomes can I realistically expect? A trustworthy provider will discuss realistic expectations rather than promising cures or guaranteed results.
• Where do your allogeneic products come from? If using donor-derived products, the provider should be able to name the tissue bank and provide cell viability data.

Red Flags

• Guaranteed results or cure claims. No legitimate stem cell provider guarantees outcomes. The biology is too variable and the evidence too early for such promises.
• Treating every condition with the same product. Clinics that offer stem cell injections for an implausibly broad range of conditions (autism, COPD, Parkinson’s, heart disease, and knee pain all under one roof) should raise serious concerns [13].
• High-pressure sales tactics. Aggressive marketing, limited-time offers, and free seminar-to-sale pipelines are common in the direct-to-consumer stem cell market and are not characteristic of evidence-based medical practice.
• No physician evaluation before treatment. A proper clinical evaluation, including history, physical examination, and imaging review, should precede any injection recommendation.
• Unwillingness to discuss risks or alternatives. Every procedure has risks. A provider who cannot or will not discuss complications, alternative treatments, or the possibility that the injection may not work is not practicing good medicine.
• Intravenous stem cell infusions for orthopedic problems. For joint-specific problems, cells should generally be injected directly into the target tissue. IV infusions for localized orthopedic issues lack a strong mechanistic rationale and may indicate a provider focused on revenue rather than outcomes.

Safety Considerations

When performed by qualified practitioners using properly prepared products, stem cell injections have a generally favorable safety profile. The most common adverse events are:

• Pain and swelling at the injection site (expected and temporary)
• Temporary stiffness in the treated joint
• Rare: infection at the injection or aspiration site
• Rare: nerve or blood vessel injury during the procedure

More serious complications have been reported with unregulated products and unqualified providers, including infections from contaminated products and vision loss from unproven intraocular stem cell injections [14]. The FDA has issued multiple warning letters to clinics marketing unapproved products.

The Bottom Line

Stem cell injections are a promising but still-evolving area of medicine. For the right patients and indications, they may offer meaningful pain relief and functional improvement with less downtime than surgery. The best approach is to seek board-certified physicians with regenerative medicine training, ask detailed questions, set realistic expectations, and consider whether a registered clinical trial might be the most responsible path.

Related Reading

• Stem Cell Therapy: Complete Guide
• Mesenchymal Stem Cells: Sources, Mechanisms, and Applications
• Peptide Therapy: Complete Guide
• Peptide Injections: Types, Technique, and What to Know

References

1. Marks PW, Witten CM, Califf RM. “Clarifying stem-cell therapy’s benefits and risks.” N Engl J Med. 2017;376(11):1007-1009. doi:10.1056/NEJMp1613723
2. Marx RE. “Platelet-rich plasma: evidence to support its use.” J Oral Maxillofac Surg. 2004;62(4):489-496. doi:10.1016/j.joms.2003.12.003
3. Filardo G, Di Matteo B, Di Martino A, et al. “Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial.” Am J Sports Med. 2015;43(7):1575-1582. doi:10.1177/0363546515582027
4. Hegde V, Shonuga O, Ellis S, et al. “A prospective comparison of 3 approved systems for autologous bone marrow concentration demonstrated nonequivalency in progenitor cell number and concentration.” J Orthop Trauma. 2014;28(10):591-598. doi:10.1097/BOT.0000000000000113
5. US Food and Drug Administration. “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use.” FDA Guidance Document. 2020.
6. Zuk PA, Zhu M, Mizuno H, et al. “Multilineage cells from human adipose tissue: implications for cell-based therapies.” Tissue Eng. 2001;7(2):211-228. doi:10.1089/107632701300062859
7. Troyer DL, Weiss ML. “Wharton’s jelly-derived cells are a primitive stromal cell population.” Stem Cells. 2008;26(3):591-599. doi:10.1634/stemcells.2007-0439
8. Berger DR, Centeno CJ, Steinmetz NJ. “Platelet lysates from aged donors promote human tenocyte proliferation and migration in a concentration-dependent manner.” Bone Joint Res. 2019;8(1):32-40. doi:10.1302/2046-3758.81.BJR-2018-0164.R1
9. Koh YG, Kwon OR, Kim YS, Choi YJ. “Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study.” Arthroscopy. 2014;30(11):1453-1460. doi:10.1016/j.arthro.2014.05.036
10. Chahla J, Dean CS, Moatshe G, et al. “Concentrated bone marrow aspirate for the treatment of chondral injuries and osteoarthritis of the knee: a systematic review of outcomes.” Orthop J Sports Med. 2016;4(1):2325967115625481. doi:10.1177/2325967115625481
11. Mardones R, Jofre CM, Tobar L, Minguell JJ. “Mesenchymal stem cell therapy in the treatment of hip osteoarthritis.” J Hip Preserv Surg. 2017;4(2):159-163. doi:10.1093/jhps/hnx011
12. Defined RG, Rundle CH, Mitchell A, et al. “Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.” Int Orthop. 2015;39(6):1271-1277. doi:10.1007/s00264-015-2741-z
13. Turner L, Knoepfler P. “Selling stem cells in the USA: assessing the direct-to-consumer industry.” Cell Stem Cell. 2016;19(2):154-157. doi:10.1016/j.stem.2016.06.007
14. Bauer G, Elsallab M, Abou-El-Enein M. “Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions.” Stem Cells Transl Med. 2018;7(9):676-685. doi:10.1002/sctm.17-0282